BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17124578)

  • 1. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
    Yasui-Furukori N; Saito M; Inoue Y; Niioka T; Sato Y; Tsuchimine S; Kaneko S
    Eur J Clin Pharmacol; 2007 Jan; 63(1):51-6. PubMed ID: 17124578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.
    Yasui-Furukori N; Saito M; Niioka T; Inoue Y; Sato Y; Kaneko S
    Ther Drug Monit; 2007 Feb; 29(1):45-8. PubMed ID: 17304149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
.
    Chen R; Shen K; Hu P
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):231-236. PubMed ID: 27936523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
    Chen R; Wang H; Shi J; Shen K; Hu P
    Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
    Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
    Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
    J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics.
    Kim JR; Woo HI; Chun MR; Lim SW; Kim HD; Na HS; Chung MW; Myung W; Lee SY; Kim DK
    Drug Des Devel Ther; 2015; 9():5247-54. PubMed ID: 26396498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
    Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
    Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism in CYP2D6 affects the pharmacokinetics and dose escalation of paroxetine controlled-release tablet in healthy Chinese subjects.
    Chen R; Shen K; Hu P
    Int J Clin Pharmacol Ther; 2017 Nov; 55(11):853-860. PubMed ID: 28933337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of paroxetine tablet in healthy Chinese volunteers].
    Zhu J; Liu WZ; Yang H; Liu WX; Wang HC; Lin YH; Liu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):260-2. PubMed ID: 18250057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.
    Ozdemir V; Naranjo CA; Herrmann N; Reed K; Sellers EM; Kalow W
    Clin Pharmacol Ther; 1997 Sep; 62(3):334-47. PubMed ID: 9333110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and comparative bioavailability of two terbinafine hydrochloride formulations after single-dose administration in Chinese healthy subjects.
    Jiang X; Wang N; Zhang ZJ; Tian Y; Chen Y
    Arzneimittelforschung; 2008; 58(7):363-6. PubMed ID: 18751504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
    Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
    Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.